Revvity, Inc. (RVTY) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and in...
Revvity, Inc. (RVTY) currently trades at a P/E ratio of 60.53 (historical range: 34.39–92.19, median: 48.77), placing it at the 89th percentile — expensive relative to its history, P/S ratio of 5.00 (range: 3.17–6.30, 71th percentile — above its historical average), EV/EBITDA of 214.53 (range: 33.17–214.53, 100th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Revvity, Inc.'s P/E ratio has contracted by 10% over the observed period (from an average of 53.2 to 47.7).
Revvity, Inc. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 60.53 | 34.39 | 48.77 | 92.19 | 89th | expensive relative to its history |
| P/S Ratio | 5.00 | 3.17 | 4.21 | 6.30 | 71th | above its historical average |
| EV/EBITDA | 214.53 | 33.17 | 75.64 | 214.53 | 100th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.03 | 0.05 | 0th | expensive relative to its history |